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Abstract 
The purpose of this study was to use liquid chromatography-mass spectrometry (LC-MS) with 
XCMS for a quantitative metabolomic analysis of UM1 and UM2 oral cancer cells after knockdown 
of metabolic enzyme adenylate kinase 2 (AK2) or phosphorylate glycerol kinase 1 (PGK1). UM1 
and UM2 cells were initially transfected with AK2 siRNA, PGK1 siRNA or scrambled control 
siRNA, and then analyzed with LC-MS for metabolic profiles. XCMS analysis of the untargeted 
metabolomics data revealed a total of 3200-4700 metabolite features from the transfected UM1 or 
UM2 cancer cells and 369-585 significantly changed metabolites due to AK2 or PGK1 suppression. 
In addition, cluster analysis showed that a common group of metabolites were altered by AK2 
knockdown or by PGK1 knockdown between the UM1 and UM2 cells. However, the set of 
significantly changed metabolites due to AK2 knockdown was found to be distinct from those 
significantly changed by PGK1 knockdown. Our study has demonstrated that LC-MS with XCMS is 
an efficient tool for metabolomic analysis of oral cancer cells, and knockdown of different genes 
results in distinct changes in metabolic phenotypes in oral cancer cells. 
Key words: Liquid chromatography-mass spectrometry; XCMS; Oral cancer cells; Adenylate kinase 2; 
Phosphorylate glycerol kinase 1. 
Introduction 
Metabolomics aims to measure the expression 
levels of low-molecular-weight metabolites in the 
context of physiological stimuli or disease states. With 
the newly evolved mass spectrometry (MS) and 
nuclear magnetic resonance spectroscopy methods, 
metabolic profiling has now become a valuable 
approach to investigate the role of metabolism in 
human diseases and identifying biomarkers for 
clinical applications [1]. In our previous study, we 
developed a metabolomics methodology based on 
capillary ion chromatography/mass spectrometry 
(Cap IC/MS) for global profiling of metabolites in 
head and neck cancer cells and cancer stem cells 
(CSCs). With this powerful tool, more than 4000 
metabolites were quantified from the cells and 
significant changes in metabolites of energy 
metabolism pathways were identified between CSCs 
and non-stem cancer cells (NSCCs) [2]. Recently we 
also demonstrated a targeted metabolomics approach 
based on IC-MS and stable isotope labeled internal 
standards for analyzing targeted metabolites in head 
and neck cancer cells and CSCs. These methods offer 
great technical advantages for metabolite analysis, 
including exquisite sensitivity, high speed and 
reproducibility, and wide dynamic range. Our 
analyses indicate that the metabolic phenotypes are 
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distinct between high and low invasive head and neck 
cancer cells and between CSCs and NSCCs [3]. In 
addition, we have shown that the metabolic defects 
introduced by siRNA silencing of metabolic enzymes 
transketolase and adenylate kinase 2 (AK2) may be 
compensated in some cancer cells by alternative 
feedback metabolic mechanisms, suggesting that 
cancer cells may overcome single defective pathways 
through secondary metabolic network adaptations 
[4].  
Similar to genomics and proteomics, MS-based 
metabolomics generates massive amount of data. 
Handling, processing and analysis of large 
metabolomics datasets can be very time-consuming 
and requires specialized mathematical, statistical and 
bioinformatics tools [5]. XCMS (xcmsonline. 
scripps.edu) is a cloud-based informatics platform 
that allows metabolomics researcher to easily upload 
and process LC-MS based metabolomics data. It 
provides a practical solution for untargeted 
metabolomic analysis workflow including feature 
detection, retention time correction, alignment, 
annotation, statistical analysis, and data visualization. 
Cloud plots generated with XCMS allows an effective 
representation of LC-MS-based metabolomics data by 
providing various information such as the p-value, 
the directional fold change, the retention time, and the 
mass-to-charge ratio of metabolic features within a 
defined threshold [6-8].  
The purpose of this study was to conduct a 
quantitative metabolomic analysis of oral cancer cells 
after knockdown of metabolic enzyme AK2 or 
phosphorylate glycerol kinase 1 (PGK1). UM1 and 
UM2 cells were initially transfected with AK2 siRNA, 
PGK1 siRNA or scrambled control siRNA, and then 
LC-MS was used to globally profile the metabolites in 
the transfected cells. Finally, XCMS and cluster 
analysis were performed to analyze the metabolomic 
data to reveal significantly altered metabolites 
following AK2 or PGK1 inhibition. Our application 
has demonstrated this method is effective to reveal 
metabolomic changes related to perturbation of key 
metabolic enzymes.  
Materials and Methods 
Cell culture  
 UM1 and UM2 cells were cultured in the 
Dulbecco’s modified eagle medium (DMEM) 
supplemented with 10% fetal bovine serum, penicillin 
(100 U/mL), and streptomycin (100 μg/mL) 
(Invitrogen, Carlsbad, CA, USA). The cells were 
maintained at 37 °C in a humidified 5% CO2 incubator 
and passaged when they reached 90−95% confluence. 
siRNA knockdown 
UM1 and UM2 cells were transfected with 
siRNA in 6-well plates using the Hilymax transfection 
regent (Dojindo Molecular Technologies, Rockville, 
MD, USA) according to the manufacturer’s 
instruction. Validated double-stranded siRNAs of 
PGK1 (sc-36215) and AK2 (sc-38906) or non-target 
control siRNAs (Santa Cruz Biotech, Santa Cruz, CA, 
USA) were mixed with the Hilymax transfection 
reagent and then added to the cell culture. After 24 h 
treatment, the siRNA-containing medium were 
removed and the cells were further cultured in the 
fresh media for 48 h prior to metabolite extraction.  
Western blotting 
Protein samples were separated with 4-12% 
Bis-Tris NuPAGE gels (Invitrogen, Carlsbad, CA, 
USA) and transferred onto nitrocellulose membranes 
by the Trans-blot SD semi-dry transfer cell (Bio-Rad, 
Hercules, CA, USA). The membrane was then blocked 
with 5% non-fat dry milk (Santa Cruz Biotech) for one 
hour, and sequentially incubated with anti-PGK1 
(Y-12, sc-17943) or anti-AK2 (H65, sc-28786) primary 
antibody (Santa Cruz Biotech) and corresponding 
secondary antibody (GE Healthcare, Piscataway, NJ, 
USA). The detection was performed with the 
ECL-Plus Western blot detection kit (GE Healthcare). 
 Metabolite extraction 
Cultured cells were quickly washed twice with 
ice-cold phosphate-buffered saline (PBS) in a cold 
room to remove medium components and then 
quickly rinsed with Milli-Q water. After removal of 
water, 400 µL of CH3OH was added to each culture 
plate. The cells were placed in liquid N2 for 10 min, 
thawed, and sonicated for 10 min. This process was 
repeated three times in order to completely extract the 
metabolites from cells.  
The combined samples from the extraction 
process were then centrifuged at 10,000 g for 5 min to 
pellet insoluble debris at 4 °C, with the supernatant 
transferred to microcentrifuge tubes and dried with a 
speed vacuum. Afterwards, each dried sample was 
resuspended, vortexed, centrifuged and transferred to 
autosampler vials for LC-MS analysis. 
LC-MS and data analysis 
Separation of metabolites was performed by 
reversed phase LC (HP1100, Agilent Technologies, 
Santa Clara, CA, USA) using a reversed-phase 
XBridge C18 column (1.7 µm particle size, 1x150 mm, 
Waters, Milford, MA, USA) and 8 µL of each sample 
was injected on the C18 column for analysis. Mobile 
phase A consisted of H2O/0.1% formic acid and the 
mobile phase B consisted of ACN with 0.1% formic 
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acid. LC gradient was as follows: T= 0 min, 95% A/5% 
B; T = 25 min, 5% A/95% B; T = 33 min, 5%A/95%B 
(for re-equilibration of column). ESI source settings on 
Agilent 6520 Q-TOF instrument were as follows: 
drying gas flow, 8 L/min; gas temp, 250 °C; nebulizer 
pressure, 25 psi; sheath flow, 9 L/min; sheath 
temperature, 350 °C; fragmentor, 135 V; capillary, 
4000 V. Mass spectral data from 70 to 1100m/z were 
collected in the positive ionization mode. All the 
samples were analyzed in triplicate.  
Data analysis was performed by the XCMS 
Online at https://xcmsonline.scripps.edu/ using 
three steps: data upload, parameter selection, and 
result interpretation. Metabolomics features were 
defined as ions with a unique m/z and retention time 
and tentative identification was done by simply 
matching the m/z measurements with the Human 
Metabolome Database (HMDB). The metabolomics 
data resulting directly from XCMS Online were used 
to generate the cloud plot [7]. The metabolic features 
that showed significant changes in the cancer cells 
with AK2 or PGK1 knockdown were used to generate 
heat maps with the NetWalker 1.0 
(https://netwalkersuite.org/).  
Results and discussion 
Adenylate kinases (AKs) are a set of enzymes 
that catalyze the nucleotide phosphoryl exchange 
reaction. Among them, AK2 is a metabolic enzyme 
expressed in the mitochondrial intermembrane space 
and plays a unique role in energy metabolism and 
transfer [9]. Recently studies show that AK2 might 
have important extra-mitochondrial functions. 
Mutation in AK2 was implicated in neutrophil 
differentiation arrest and sensorineural deafness[10]. 
Homozygous AK2 mutated embryos of Drosophila 
melanogaster ceased growth and died before reaching 
the third instar larval stage, indicating AK2 is 
indispensable for cell proliferation and development 
[11]. PGK1 is a glycolytic enzyme that catalyzes the 
conversion of 1,3-diphosphoglycerate to 
3-phosphoglycerate. It is regulated by 
hypoxia-inducible factor-1α (HIF-1α) and has been 
demonstrated to involve in cell growth, angiogenesis, 
DNA replication/repair and cancer metastasis 
[12–15]. In order to assess the effect of PGK1 
down-regulation ona metabolomic changes in oral 
cancer cells, we first used siRNA to knock down 
PGK1 expression in the UM1 and UM2 cells. As 
shown in Fig. 1, siPGK1 transfection led to a 
significant decline in the expression of PGK1 in both 
UM1 and UM2 cancer cells. Similarly, the expression 
level of AK2 was also significantly inhibited in UM1 
and UM2 cells after siAK2 transfection.  
 
 
Figure 1.  Knockdown of AK2 or PGK1 expression in the UM1 and UM2 
oral cancer cells with siRNA. (A) Western blot analysis of AK2 and PGK1 
expression in UM1cells transfected with siRNA control (siCTRL), AK2 siRNA 
(siAK2) or PGK1 siRNA (siPGK1). (B) Western blot analysis of AK2 and PGK1 
expression in the UM2 cells transfected with siCTRL, siAK2 or siPGK1.  
 
Both UM1 and UM2 cell lines are used in this 
study. They were initially established from the same 
tumor of a tongue cancer patient. However, UM1 cells 
are highly invasive whereas UM2 cells are low 
invasive[16]. Due to a large number of metabolites 
present in a biological sample and the wide dynamic 
concentration range of the compounds, characterizing 
the metabolome has been an analytical challenge. 
Here we have demonstrated that LC-MS with XCMS 
is an efficient tool for metabolomic analysis of UM1 
and UM2 oral cancer cells. The LC-MS/MS data was 
analyzed through the XCMS Online with the 
following steps: uploading data, selecting parameters, 
and analyzing/visualizing data. Fig.2 shows the 
XCMS cloud plots of the quantitative metabolomic 
analysis results. With a stringent criteria of P<0.01 and 
fold change ≥1.5, 155 or 164 metabolic features were 
found to be significantly altered pertaining to AK2 or 
PGK1 down-regulation respectively. The cloud plot 
allows to present the information about metabolic 
features including p-value, the directional fold 
change, the retention time, and the mass-to charge 
ratio. In addition, the total ion chromatograms for 
each sample and the time-dependent composition of 
the mobile phase are shown. The intensity of features 
that is increased are shown as green dots on the top 
plot, whereas the features whose intensity is 
decreased are shown on the bottom plot in red. The 
size of each bubble corresponds to the log fold change 
of the feature. The larger the bubble the bigger the 
changes in levels, as calculated by the Welch t-test 
with unequal variances used calculate the statistical 
significance of the fold change. The fold change is 
represented by the intensity of the feature’s color 
where features with high p-values are darker in 
compared with features with low p-values. The y 
coordinate of each feature corresponds to the mass-to 
charge ratio of the compound which is determined by 
MS.  
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Figure 2. Cloud plots present the metabolite features that are significantly altered between the cells transfected with siCTRL and those transfected with siAK2 (Fig. 
2A) or siPGK1 (Fig. 2B) for knockdown. 
 
In total, LC-MS with XCMS allows to detect 4280 
changed metabolic features in the UM1 cells and 3183 
changed metabolic features in the UM2 cells following 
AK2 knockdown respectively. Among these large lists 
of metabolites altered by siRNA knockdown, 448 
metabolic features (339 downregulated and 109 
upregulated) were found to be significantly changed 
in the UM1 cells and 369 metabolic features (225 
downregulated and 114 upregulated) were found to 
be significantly changed in the UM2 cells (P< 0.05). 
Similarly, 4736 metabolic features were altered in the 
UM1 cells and 4212 metabolic features were altered in 
the UM2 cells after PGK1 knockdown. Among them, 
585 metabolites (300 downregulated and 285 
upregulated) in the UM1 cells and 417 metabolic 
features (316 downregulated and 101 upregulated) in 
the UM2 cells were altered significantly (P < 0.05) 
(Fig. 3).  
By comparing the significantly changed 
metabolic features between UM1 and UM2 cells, 85 
metabolites were both detected in UM1 (64 
downregulated and 21 upregulated) and UM2 cells 
(61 downregulated and 24 upregulated) after AK2 
knockdown (Fig. 4). Similarly, 96 metabolites were 
commonly found between UM1 (65 downregulated 
and 31 upregulated) and UM2 cells (67 
downregulated and 29 upregulated) following PGK1 
knockdown (Fig. 4). However, our analysis indicates 
that the changes in metabolic features were distinct 
between the cancer cells with AK2 and those with 
PGK1 knockdown.  
As Schulze and Harris stated that profiling 
metabolites of cancer is difficult using MS because 
some metabolites were present with overlapping 
spectral peaks [17]. However, using XCMS for 
analysis of MS-based metabolomic data, metabolites 
can be well resolved and identified by using both 
accurate mass and retention time. The alignment 
procedure for retention time in XCMS helps to 
eliminate insignificant groups of peaks [18]. 
Eliminating these low resolution groups and 
incomplete signals using retention time alignment 
steps allows to select the peak groups with high 
intensity and good peak shape and to match peaks 
among samples very precisely [18]. 
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Figure 3. The changes in metabolic features in oral cancer cells following the inhibition of metabolic enzymes. (A) The total number of metabolic features detected 
in the UM1 and UM2 cancer cells and the number of metabolic features that are significantly altered by either siAK2 or siPGK1 in the UM1 or UM2 cells. (B) Common 
set of metabolites between UM1 and UM2 cells that are significantly altered by AK2 knockdown. (C) Common set of metabolites between UM1 and UM2 cells that 
are significantly altered by PGK1 knockdown. 
 
 
Figure 4. The number of upregulated/downregulated metabolic features in UM1 or UM2 cells due to AK2 or PGK1 knockdown. (A) The number of 
upregulated/downregulated metabolic features that were significantly changed in UM1 or UM2 cells with either AK2 or PGK1 knockdown (B) The number of 
upregulated/downregulated metabolic features which were commonly changed between UM1 and UM2 cells with AK2 or PGK1 knockdown. 
 
As shown in Fig. 5, heat maps were generated 
with the NetWalker 1.0 program based on the 
significantly changed metabolites in the UM1 and 
UM2 cells after knockdown of AK2 or PGK1. Each 
row in the heat map represents a metabolic feature 
and the color indicates the expression levels of 
metabolic features between knockdown and control 
cells. Interestingly, as shown by the heat maps, there 
is a similar metabolic profile change caused by siAK2 
knockdown between UM1 and UM2 cells. Similar 
heat maps were also observed between the UM1 and 
UM2 cells with siPGK1 knockdown. However, it 
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should be noted that the set of metabolites that show 
significant difference between siPGK1 and siCTRL are 
completely distinct from the set of metabolites that 
show significant difference between siAK2 and 
siCTRL, suggesting that knockdown of different 
genes results in the changes in different set of 
metabolites. Some tentatively identified metabolites 
are listed in Supplemental Tables S1 and S2. They 
were simply matched by submitting m/z 
measurements to search against the HMDB database. 
Therefore, further verification is absolutely needed to 
confirm the identity of these metabolites. One of the 
potential metabolites significantly down-regulated in 
both UM1 and UM2 cells after AK2 knockdown was 
found to be cysteamine, which is an aminothiol and 
anti-oxidant that has potential for the treatment of 
radiation sickness and neurological disorders. In 
addition, it has been demonstrated to have anti-cancer 
effects in different types of cancers [19–21]. The 
reduced expression of cysteamine following AK2 
inhibition suggests that oral cancer cells survived 
from AK2 knockdown might have a potential to 
become even more aggressive.  
As a summary, our studies have demonstrated 
that LC-MS with XCMS is a highly effective 
methodology for untargeted metabolomic analysis of 
oral cancer cells. A single LC-MS based analysis less 
than 40 minutes allowed to detect more than 4000 
metabolic features from oral cancer cells and reveal 
significantly altered metabolites in oral cancer cells 
due to AK2 or PGK1 knockdown. Cluster analysis of 
the results after XCMS analysis of the metabolomic 
data showed similar heat maps for the significantly 
altered metabolites between UM1 and UM2 cancer 
cells. However, the set of metabolites showing 
significant difference between siPGK1 and siCTRL are 
completely distinct from the set of metabolites 
showing significant difference between siAK2 and 
siCTRL, suggesting that knockdown of different 
genes results in the changes in different set of 
metabolites.  
 
 
Figure 5. Heat maps for the significantly changed metabolites in the UM1 and UM2 cells after knockdown of AK2 (A) or PGK1 (B). 
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